A clinical-stage biotechnology company creating a new class of drugs today (Feb 20) announced that a first subject has been dosed in a phase 1 clinical trial.
Certara launches version 18 of its physiologically-based pharmacokinetic (PBPK) Simcyp Simulator with new features including advanced food staggering and tumor models to optimize trial design and dose selection.
In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets...
Impel Neuropharma announced the first participant have been dosed in a Phase I trial looking at safety and tolerability for the company’s intranasal olanzapine product.
Certara has developed a new licensing approach, which provides smaller organizations access to its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform.
WuXi PharmaTech has signed a strategic partnership deal to provide exclusive laboratory testing services to Hong Kong-headquartered Lee’s Pharmaceutical.
A bioanalytical consultant has stressed the importance of drug developers testing commercial off-the-shelf (COTS) software following the discovery of potential issues with Thermo Scientific’s bioequivalence Kinetica platform.
ADME/toxicity testing firm Cyprotexservice providers is bringing researchers free online access to its database of ADME and pharmacokinetic properties of marketed drugs, through Cloe Knowledge.
MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.
US contract development firm Azopharma has begun offering microdosing at its AvivoClin facility in Daytona Beach, Florida, joining market leaders like Xeleron and Covance in the Phase 0 trial sector.
MDS Pharma is continuing its efforts to move on from the trouble
caused in its Pharma Services segment by a US Food and Drug
Administration (FDA) review of its Montreal-area bioanalytical
facilities.
ADME/toxicity service providers, Cyprotex, launch a new service to
help drug discovery groups assess new oral drug candidates. The
service will equip researchers with new pharmacokinetic insights as
early as possible, aiming to improve...
Nanostream, has introduced a fraction collector add-on to its
Veloce system, transforming it into a front-end sample preparation
tool that lets users rapidly perform MS assays.
